Clinical Scorecard: Association of UGT1A1 Genetic Variants with Hyperbilirubinemia in Newborns Identified through Genetic Screening

At a Glance

Key Highlights

• Study involved 1,019 newborns screened for UGT1A1 variants
• Confirmed biallelic or multi-allelic UGT1A1 variants in 75 newborns
• Higher TcB levels observed at 6 weeks in mutation groups compared to controls
• Clinically significant hyperbilirubinemia was rare among both mutation and control groups
• Common UGT1A1 variants classified as moderate-/high-risk may increase genetic counseling burden

Guideline-Based Recommendations

Diagnosis

• Diagnosis based on serum bilirubin levels and clinical manifestations

Management

• Phototherapy and phenobarbital for Crigler–Najjar syndrome type II

Monitoring & Follow-up

• Monitor bilirubin levels at prespecified timepoints

Risks

• Potential for bilirubin encephalopathy in severe cases of UGT1A1 deficiency

Patient & Prescribing Data

Full-term singleton newborns with no structural or chromosomal abnormalities

Routine genetic screening may identify risk for hyperbilirubinemia

Clinical Best Practices

• Consider UGT1A1 screening in newborn genetic screening programs
• Classify common UGT1A1 variants for genetic counseling

Related Resources & Content

• Expert Consensus on NGS-based Screening